All content on this website is provided for educational and research purposes only. It does not constitute medical advice or treatment. This article discusses biological mechanisms also observed in laboratory and preclinical research models, so no clinical efficacy or safety for human use is implied. The substances discussed, which are not registered medicines, are not intended for use in humans or animals.

FOXO4-DRI peptide

FOXO4-DRI peptide is an experimental synthetic peptide studied for its potential role in cellular aging and senescence biology. It was developed as part of research exploring molecules that could selectively influence senescent cells, which accumulate in tissues during aging.

FOXO4-DRI was designed to interfere with the interaction between FOXO4 and p53, two proteins involved in cellular stress responses and survival pathways.

Because of this mechanism, FOXO4-DRI has been investigated in research related to senolytics, a class of compounds aimed at selectively targeting aging or damaged cells.

The peptide remains an experimental research compound and has not been approved as a pharmaceutical medication by major regulatory authorities.

How FOXO4-DRI peptide works

FOXO4-DRI peptide was designed to disrupt the interaction between FOXO4 and p53 proteins inside certain cells.

Experimental studies suggest that this interaction plays a role in maintaining the survival of senescent cells, which are cells that have stopped dividing but remain metabolically active. Research indicates that FOXO4-DRI may:

  • interfere with FOXO4–p53 binding in senescent cells

  • alter signaling pathways associated with cell survival and apoptosis

  • influence biological processes related to cellular aging and tissue homeostasis

Because senescent cells accumulate in many tissues over time and may contribute to age-related changes, compounds affecting these pathways are being studied in the field of longevity and aging biology.

However, the precise biological effects of FOXO4-DRI in humans remain uncertain.

Clinical trials and evidence

Research involving FOXO4-DRI has primarily been conducted in laboratory studies and animal models. Experimental studies have explored:

  • mechanisms of cellular senescence and aging biology

  • the effects of FOXO4-DRI on senescent cells in experimental systems

  • potential impacts on tissue function in aging models

Some preclinical studies have suggested that disrupting FOXO4–p53 signaling may influence the survival of senescent cells in laboratory models.

However, FOXO4-DRI has not undergone extensive clinical trials in humans, and most available data come from preclinical research rather than controlled clinical studies.

Further investigation is required to determine whether these findings could translate into future therapeutic applications.

Possible side effects of FOXO4-DRI:

Because FOXO4-DRI has primarily been studied in experimental settings, its complete safety profile in humans has not been fully established. Possible or theoretical side effects may include:

  • fatigue

  • headache

  • changes in cellular stress signaling pathways

  • injection site reactions

As with other investigational compounds that influence cellular survival mechanisms, further research is required to clarify the long-term safety and potential risks.

FOXO4-DRI is considered an experimental peptide studied primarily in aging and senescence research and is not approved as a prescription medication by major regulatory authorities. Scientific research involving such compounds should be conducted with appropriate safety precautions and in accordance with applicable laws and regulations in the relevant country.

The purpose of this website is to provide clear, evidence-based information about biologically active compounds often discussed in research, metabolic health, and biohacking communities. The information presented here is educational and should not be considered medical advice.

FOXO4-DRI
Action: Senescent cell removal | Category: senolytic peptide
Experimental dosage: 250 mcg | Frequency: every day | Timing: freely | Cycle on: 3-4 months — Route: subcutaneous (SC). Stop rules: hold and seek medical advice if moderate/severe adverse effects occur (e.g., escalating nausea/vomiting, dizziness, palpitations, significant blood pressure changes, severe injection‑site reactions, allergic symptoms) or if there is no clear ‘return‑to‑baseline’ window between doses. | Cycle off: 2 months
Effectiveness: ■■▢▢▢ | Safety: ■■▢▢▢

Related peptides

Peptides from the same functional group:Epithalon

Our peptides database

5-Amino-1MQ | AICAR peptide | AOD9604 peptide | Arg-BPC-157 peptide | BPC-157 peptide | CagriSema | Cerebrolysin peptide | CJC-1295 NO DAC peptide | CJC-1295 with DAC peptide | Cortagen peptide | Dihexa peptide | DSIP peptide (Delta Sleep-Inducing Peptide) | Dulaglutide peptide | Epithalon peptide | Exenatide peptide | Follistatin 315 peptide | Follistatin 344 peptide | FOXO4-DRI peptide | GHK-Cu peptide | GHRP-2 peptide | GHRP-6 peptide | Hexarelin peptide | HGH Fragment 176-191 | Humanin peptide | IGF-1 LR3 peptide | Ipamorelin CJC-1295 NO DAC | Ipamorelin peptide | Kisspeptin peptide | KPV peptide | L-Carnitine | Liraglutide peptide | Livagen peptide | LL-37 peptide | Matrixyl peptide | Mazdutide peptide | Melanotan II peptide | Melanotan peptide | MGF peptide (Mechano Growth Factor peptide) | MOD GRF 1-29 | MOTS-C peptide | NAD+ coenzime (Nicotinamide Adenine Dinucleotide) | Oxytocin peptide | P21 peptide | PEG-MGF peptide | Pinealon peptide | PT-141 peptide (Bremelanotide) | PTD-DBM peptide | Retatrutide | Selank peptide | Semaglutide | Semax peptide | Sermorelin peptide | SHLP-2 peptide | SHLP-6 peptide | Somatropin peptide | SS-31 peptide (Elamipretide) | TB-500 peptide | Tesamorelin peptide | Thymosin Alpha 1 peptide | Thymosin beta 4 peptide | Thymosin β10 peptide | Thymulin peptide | Tirzepatide | Vilon peptide
Tagged